Introduction
Donor--recipient (D--R) alloreactivity may result in either graft versus host disease (GVHD) or graft rejection in allogeneic stem cell transplant (SCT) recipients, compromising outcomes. In human leukocyte antigen (HLA) matched SCT donor--recipient pairs, alloreactivity derives, in part, from minor histocompatibility antigen (mHA) differences. 1 probabilistic despite increasing stringency of HLA matching and improvements in SCT technique. 3--5 Refinement in molecular characterization of the HLA loci has resulted in superior survival in SCT in D--R pairs matched at high--resolution. 6, 7 Thus, molecular HLA compatibility testing incorporating HLA--A, B, C, and DRB1 has become standard of care for recipients of unrelated donor allografts. Despite this advance in histocompatibility testing, GVHD associated with D--R alloreactivity and subsequent delays in immune reconstitution remain problematic. Profiling known mHA is of limited utility in the larger context of population--based donor identification because the immunogenicity of specific mHA depends on the HLA phenotype of the patient, since individual mHA are presented efficiently only on certain HLA molecules and not on others. 8--10 Thus, donor selection algorithms in use at present leave the recipient at risk for GVHD due to the lack of knowledge of the larger antigenic landscape, as viewed from the frame of reference of the donor immune effector cells such as T and B cells. Hypothetically, such a landscape would incorporate the information on the catalogue of mHA 'visible' to the donor and recipient T cells, and thus would represent an 'alloreactivity potential' for a D--R pair, analogous to the concept of potential energy in physics. This latent alloreactivity potential would manifest as either GVHD or graft rejection following SCT. Importantly, current conditioning regimens as well as GVHD prophylaxis regimens have been developed for use in both HLA--matched related and unrelated donor SCT in the absence of this information, which may represent an important variable in determining post transplant outcomes.
Next generation sequencing (NGS) has made it possible to comprehensively examine the role of genomic variation between donors and recipients in outcomes observed following SCT. In this report we focus on whole exome sequencing (WES), which assays only those nucleotides that code for proteins. It is likely that variation in the exome is a major source of alloreactivity because of its influence on mHA. Therefore, WES has the potential to refine donor selection algorithms by cataloging all the D--R sequence differences that may be recognized as immunogenic by either donor or recipient immune effectors. Knowledge of the entire library of antigenic disparity may allow immunosuppressive regimens of appropriate intensity to be deployed for each D--R pair, to most effectively neutralize the alloreactivity potential in an individualized manner to optimize the SCT outcomes. In this paper the findings of a pilot study examining the extent of variation in the exomes of HLA matched SCT donor--recipient pairs is reported, identifying frequent sequence variation between the two, and therefore a large alloreactivity potential.
Methods.

Patients
Patients with recurrent hematological malignancies in complete or partial remission were enrolled on a prospective clinical trial approved by the Virginia Commonwealth University Institutional Review Board (VCU--IRB) (Clinicaltrials.gov identifier: NCT00709592). The study is a randomized phase II trial of reduced intensity conditioning regimen incorporating anti--thymocyte globulin (ATG) and 450 cGy total body irradiation for allogeneic SCT in patients with recurrent hematological malignancies. 
Whole exome sequencing
Approval was obtained from the VCU--IRB to retrospectively acquire cryopreserved pre--transplant DNA samples from patients enrolled on this trial, and their donors to perform whole exome sequencing. For this analysis the DNA samples were de--identified and coded. TruSeq exome enriched libraries were prepared from the de--identified, donor--recipient pair DNA samples following standard Illumina protocol. Donor and recipient sequences were compared with each other to identify all the SNPs in the D--R pair. WES and SNP library generation protocol, and methodology for comparison between the donors and recipients is outlined in Table 1 .
Determining exome differences between donors and recipients
The annotated SNP differences between donor and recipient samples were coded according to functionality as being either synonymous or nonsynonymous, and amongst the latter as either conservative or nonconservative or stop. To correlate the donor--recipient exome sequence difference with the risk of clinical outcomes such as GVHD incidence, the vector of the change was analyzed with respect to the donor. If the recipient sample contained a polymorphism not present in the donor, the SNP at that position was counted as being in the graft versus host (GVH) direction. Reciprocally, if the recipient sample did not contain a polymorphism present in the donor this was counted as being in the host versus graft direction (HVG) (manuscript in preparation). 13 The total counts for functional SNPs 
Results.
Marked whole exome sequence difference between HLA matched donors and recipients
Whole exome enriched libraries were prepared from the nine D--R pair DNA samples (Supplementary Table 2 ). The D--R alloreactivity potential was estimated by quantifying the sequence variation between donors and recipients, with the initial examination of the donor--recipient exome differences focused on the major histocompatibility locus. The HLA region exome sequences of each recipient was WES data from the entire exome were then considered, examining all the differences at the SNP level.
The average difference between the whole exome of actual HLA matched donors and recipients was large, averaging 13,423 single nucleotide polymorphisms per actual HLA matched D--R pair, of which an average 6,445 were nonsynonymous. However, unlike the MHC locus where the nucleotide variation between simulated D--R pairs was greater as compared to actual D--R pairs, no substantial increase in SNP variation was observed at the exome level when recipients were compared with donors from other non--HLA matched pairs ( Figure 1B ). This observation implies that sequence variation across the remaining exome in SCT donors and recipients is frequent and independent of HLA matching, and may potentially contrbute to alloreactivity.
Greater exome variation in HLA--matched unrelated donors
Next WES differences between actual HLA--matched unrelated and related donors were further characterized to determine the alloreactivity potential which exists in each D--R pair. Nonsynonymous 
Equal alloreactivity potential vectors in the GVH and HVG directions
Polymorphisms present in the recipient and absent in the donor are more likely to result in GVHD because the donor T cells would lack tolerance to the mHA in the recipient tissue. Therefore the conservative and nonconservative nonsynonymous polymorphisms in the D--R pairs were examined with reference to their presence in either only the recipient (GVH direction) or the donor (HVG direction) or both. As with total allo--reactivity potential, the nonconservative variants in the GVH direction were more prevalent in the exomes of MUD SCT recipients (P=0.016; Figure 3A , Supplementary Table 3) . Importantly, the alloreactivity potential vectors (frequency of polymoprhisms in either GVH, or HVG direction) were of a similar magnitude in both the GVH and HVG directions 
Uniform distribution of SNPs across the exome
To determine whether these polymorphisms were concentated in certain regions within the exome they were mapped to the individual chromosomes in each D--R pair. A composite figure depicting the findings demonstrates that the polymorphisms are distributed over the entire genome ( Figure 5 ). This is true for both the GVH and HVG directions (data for HVG not shown). A close examination of the distribution of the exome varaints in this, admitedly small cohort, revealed that the frequency of occurrence of polymorphisms does not appear to be random, with a small number of genes demonstrating frequent variation and others with a logarithmically diminishing frequency ( Figure S1 ).
Further, the differences across the exome are equally as numerous as they are across the MHC region on chromosome 6p. Once again, consistent with the data depicted in figure 1 , the variation is less so in the MHC region of MRD when compared with URD.
Discussion.
Since the early days of SCT, the criteria for donor selection have progressed from serologically matching both alleles of 3 major histocompatibility loci (6/6; HLA--A, B and DRB1) to the current standard of matching 4--5 loci at the allele level (8/8 or 10/10; with HLA--C and DQB1 added). 14, 15 The risk of GVHD in D--R pairs matched for these loci, though lower relative to those with one or more mismatches, is still substantial. 16, 17 Further evidence for the importance of genomic loci beyond the canonical HLA molecules is demonstrated by recipients, receiving a SCT from a MHC haplotype mismatched unrelated donor, who is otherwise matched at allele level for the HLA--A, B, C and DRB1 loci, having increased odds for developing GVHD, or diminished odds for relapse. 18, 19 These findings clearly show the influence of genetic variation on SCT outcome that is not accounted for by current D--R matching standards and may be addressed using NGS. 20, 21 In our patients, WES demonstrated significant variability in the MHC loci in these HLA matched D--R pairs, and more importantly it revealed extensive coding differences in the exomes of these individuals beyond the MHC region. The latter indicates the heavy and inevitable burden of histo--incompatibility that exists in SCT recipients, despite ever more stringent HLA compatibility testing.
Whereas the risk of disease relapse is in part determined by its biological features, is critical in determining alloreactivity potential in transplantation. 39 This leads to the need for developing techniques that will give an accurate estimate of such variation.
A major advantage of WES in the transplant clinical context is that any variation between the donor and recipient will be accounted for, as observed in our data set. Although the impact of rare large--scale defects, such as gene deletions is not measurable using our analytic technique, the D--R exome variation noted nonetheless is substantial, particularly when comparing HLA--matched related and unrelated donors. The greater variation in MUD compared with MRD D--R pairs, was observed consistently despite increasing depth of analysis. It is to be noted that the oligopeptides resulting from exome variation may not all have equal immunogenicity; indeed some may not be immunogenic at all.
This may be the result of factors such as, variable binding affinity of the 'non--self' oligopeptides to the HLA molecules in a unique D--R pair (thus varying presentation), or variable expression of the SNP bearing genes or even the lack of protein cleavage sites in the vicinity of the polymorphic locus, such that immunogenic oligo--peptides are not generated. However, the more numerous variant SNPs are in a given D--R pair, logically, the greater the probability of variant peptides being presented to donor T cells, with alloreactivity (GVHD or conversely, graft rejection) developing in the recipient following SCT.
Thus the finding of greater exome variation in MUD D--R pairs both quantifies and provides a biological basis for greater alloreactivity potential when compared with MRD. Importantly, this provides rationale for investigating haplo--identical related donors in preference to single locus HLA--mismatched unrelated donors, particularly using modern conditioning and GVHD prophylaxis regimens. Further, the equivalence observed in the exome variation in the GVH and HVG in our data set, not only underscores the importance of appropriate conditioning and GVHD prophylaxis intensity in allogeneic SCT, but also highlights the value of pursuing tolerance induction strategies in solid organ transplantation.
The extensive library of SNPs observed in the exomes of HLA--matched donors and recipients, by quantifying the potential antigenic disparity between the two, also provides a partial explanation of the complex oligoclonal T cell repertoire observed following SCT. 12, 46 Based on these data we propose that the post--transplant T cell clonal expansion may be a function of the sequence variation in the donor recipient exome. However, rather than being a direct linear relationship, this will most likely be a complex interaction depending on the binding affinity of all the potential non--self oligopeptides in the D--R pair to the HLA class I and II molecules in that pair. Thus, HLA will serve as a filter for selecting out the immunogenic peptides, much as a colored filter allows only certain frequencies of white light to pass through. Consequently, the total number of SNPs leading to an immunogenic oligopeptide will be proportional to the total number of nonsynonymous SNPs. A caveat to this hypothesis however is that immune reconstitution, thus T cell repertoire following SCT is impacted by several other variables, such as the recipient microbiome, and pathogens encountered as well as the immunosuppressive therapy administered.
In this paper, WES performed on HLA--matched donor recipient pairs, revealed that in each D--R pair
there exists an extensive 'library' of potentially immunogenic sequence differences, not accounted for by conventional histocompatibility testing techniques. Given the small cohort of patients examined in this study, the value of WES in donor selection algorithms remains to be determined, however, we posit that if determined in large cohorts of patients, measuring D--R alloreactivity potential by WES may lead to an improved understanding and estimation of GVHD and graft rejection risk. This will in turn help optimize immunosuppressive therapy following transplantation and maximize treatment benefit.
We are assembling a larger cohort of patients to examine this question further.
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2 Libraries validated on BioAnalyzer, quantified using qPCR and pooled.
3
Exome enrichment. Two hybridizations performed using target specific biotinylated oligos followed by binding to magnetic streptavidin beads and three washes. PCR amplification of enriched product performed. Validation and sequencing on Illumina HiSeq 2000 with 4--8 samples per lane.
4
The 100 bp paired end FASTQ reads generated by the sequencer run through the Next--generation Sequencing Quality Control (NGS QC) Toolkit 40 to select high quality (HQ) reads, i.e., reads where at least 70% of the bases had a quality score of ≥25. An average 20% reads excluded due to this HQ filtering.
5
HQ reads aligned to the Human Genome (hg18) using CLC Bio Assembly Cell version 3.22. >91% of the HQ reads aligned with at least 95% of the bases matching over 95% of the read length. The alignments converted to the industry--standard Binary sequence Alignment/Map (BAM) format.
6 SAMtools 41 used to remove PCR duplicates from the BAM files as these may bias subsequent SNP calling. All samples with at least 28X average coverage of the entire human exome, ensuring credible and accurate SNP calling.
7
SNP calling performed with preprocessed BAM files using the Broad Institute's Genome Analysis Toolkit 42 (GATKv1.6).
The GATK SNP calling 43 involved three steps; 1. DNA insertion--deletion (INDEL) realignment; 2. Quality score recalibration; 3. SNP discovery and genotyping. The SNP caller generates a multi--sample VCF (variant--calls file).
8
The multi--sample VCF file filtered to remove chromosomal positions, which did not have at least 10X coverage and did not exceed 500X coverage. Insertion/deletion variants removed using VCFtools software (v.0.1.9.0). 44 
9
Each sample was separated from the multi--sample VCF file into individual files and positions containing missing genotype data removed. Since the original VCF file contained multiple samples, every alternate allele that occurred in any of the samples was represented.
10
To annotate the SNPs, the alternate allele and genotype data was transformed into an ANNOVAR--acceptable format primarily consisting of a single alternate allele and a genotype containing only combinations of zero and one.
11
Transformed data samples underwent independent comparison and annotation. 1. Recipient samples were compared to the actual donor and to every other donor sample to generate actual matches (recipient with its HLA--matched donor) and simulated donor--recipient matches (recipient with other, HLA--unmatched donor). 2. For annotation, files were first filtered to remove any positions where the genotype was the same as the reference and then annotated using ANNOVAR (v.2012Mar08). 45 
12
The sample--pair comparison files were then combined with the annotation files by comparing the variant alleles in sample 1 and sample 2, then annotating the variant position based on which sample contains the SNP. Figure S1 . Distribution of variant nucleotides across specific genes, individual genes depicted on X axis with frequency of polymorphism on the y--axis (n=9 D--R pairs). (A) SNPs present in specific genes in the GVH direction.
(B) SNPs present in specific genes in the HVG direction. Specific genes demonstrate varying frequency of mutation, such that, as the number of genes evaluated goes up, the number of polymorphic genes goes up logarithmically.
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